Cooperative Agreement U01DA060704
Award Date
8/15/24
Completion Date
4/30/27
Dollars Obligated
$12M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $3,287,052 to Virogenomics Biodevelopment, Inc. to advance the development of the CD74-targeting compound DRHQ as a potential treatment for stimulant use disorder, specifically methamphetamine addiction. The key objectives of this project are to conduct IND-enabling studies and a Phase I clinical trial to evaluate the safety of DRHQ in both...
This $1,594,478 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a 5-year prospective, observational study of 300 participants initiating treatment with medications for opioid use disorder (MOUD). The key objectives are to: 1) curate a dataset of craving patterns during MOUD using continuous wearable sensor data; 2) model craving trajectories and examine factors associated with opioid use...
The National Institute on Drug Abuse (NIDA) awarded a $2,134,928 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Regents of the University of Minnesota. The grant aims to develop novel, brain-penetrant, small molecule biased allosteric modulators (BAMs) of the neurotensin receptor 1 (NTSR1) to attenuate relapse to opioid seeking in individuals with opioid use disorder (OUD). Specifically, the research will: Validate NTSR1 as a drug target for the treatment...
The National Institute on Drug Abuse (NIDA) awarded a $139,000 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Temple University to investigate the ability of the chemokine receptor antagonist AMD3100 to reduce heroin self-administration and relapse behaviors in animal models. The researchers will examine the role of the chemokine receptor CXCR4 in dopaminergic neurons within the ventral tegmental area in modifying heroin taking behaviors. This work aims to...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $275,253 to Epivario Inc. to develop a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The research aims to screen and evaluate next-generation inhibitors of the metabolic enzyme ACSS2, which has been shown to play a key role in the consolidation of drug-related memories and neuroplasticity. This project...
This $3,096,164 federal Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a study to evaluate the efficacy and implementation of a peer-led Motivational Interviewing (MI) intervention called MI-CHANCE. The intervention aims to promote uptake of drug checking services and safer drug use behaviors to reduce overdose incidence among people who use drugs in San Diego County. The project will conduct a...
This federal Project Grant award of $326,410 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a two-phased clinical study to evaluate the feasibility and efficacy of a hand-held, automated, personalized oral liquid dispensing system (COPA) for delivering take-home methadone to patients with opioid use disorder (OUD). The initial feasibility study will assess the functionality and acceptability of COPA for methadone...
This $4,920,000 federal Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a randomized controlled trial to investigate the feasibility, acceptability, and preliminary effectiveness of intramuscular naltrexone as a preventive measure for opioid overdose in individuals using stimulants and living with or at risk of HIV. The study will be conducted at the University of California, San Francisco (UCSF) at...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $475,500.00 to fund research aimed at developing novel therapies to reverse fentanyl overdose. The primary goals of the research are to: 1) Screen a library of cannabidiol (CBD) analogs to identify potent negative allosteric modulators (NAMs) of the mu opioid receptor (MOR) that can attenuate fentanyl's signaling across multiple pathways,...
This $1,749,120 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research focused on understanding the underlying neurobiology and behavioral mechanisms driving the incubation of craving for the opioid oxycodone. The research team at Oregon Health & Science University will use an animal model to investigate how specific neural pathways and synaptic plasticity changes in the nucleus...